University of Gothenburg Vaccine Research Institute, Department of Microbiology and Immunology, The Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden.
Vaccine. 2010 Oct 8;28(43):6977-84. doi: 10.1016/j.vaccine.2010.08.047. Epub 2010 Aug 20.
Enterotoxigenic Escherichia coli (ETEC) is an important cause of diarrheal disease and deaths among children in developing countries and the major cause of traveller's diarrhea. Since surface protein colonization factors (CFs) of ETEC are important for pathogenicity and immune protection is mainly mediated by locally produced IgA antibodies in the gut, much effort has focused on the development of an oral CF-based vaccine. We have recently described the development of recombinant strains over-expressing CFA/I; the most prevalent CF among human clinical ETEC isolates. Here, non-toxigenic recombinant E. coli strains over-expressing Coli surface antigen 2 (CS2), CS4, CS5, and CS6, either alone, or each in combination with CFA/I were constructed by cloning the genes required for expression and assembly of each CF into expression vectors harboring a strong promoter. Immunological assays showed that recombinant strains expressing single CFs produced those in significantly larger amounts than did corresponding naturally high producing reference strains. Recombinant strains co-expressing CFA/I together with another CF also expressed significantly larger amounts of both CFs compared with the corresponding references strains. Further, when tested in mice, oral immunization with formalin-killed recombinant bacteria co-expressing one such double-expression CF pair, CFA/I+CS2, induced specific serum IgG+IgM and fecal IgA antibody responses against both CFs exceeding the responses induced by immunizations with natural reference strains expressing CFA/I and CS2, respectively. We conclude that the described type of recombinant bacteria over-expressing major CFs of ETEC, alone or in combination, may be useful as candidate strains for use in an oral whole-cell CF-ETEC vaccine.
肠产毒性大肠杆菌(ETEC)是发展中国家儿童腹泻病和死亡的重要原因,也是旅行者腹泻的主要原因。由于 ETEC 的表面蛋白定植因子(CFs)对于致病性很重要,并且免疫保护主要是通过肠道中局部产生的 IgA 抗体介导的,因此人们已经投入了大量精力来开发基于 CF 的口服疫苗。我们最近描述了过表达 CFA/I 的重组菌株的开发;CFA/I 是人类临床 ETEC 分离株中最常见的 CF。在这里,通过将每个 CF 的表达和组装所需的基因克隆到含有强启动子的表达载体中,构建了单独过表达 Coli surface antigen 2 (CS2)、CS4、CS5 和 CS6 的非毒性重组大肠杆菌菌株,或者将这些 CF 与 CFA/I 一起过表达。免疫测定表明,表达单个 CF 的重组菌株产生的 CF 量明显大于相应的天然高产生参考菌株。共表达 CFA/I 和另一种 CF 的重组菌株也表达了明显更多的 CFs,与相应的参考菌株相比。此外,当在小鼠中进行测试时,用福尔马林灭活的共表达一种此类双表达 CF 对的重组菌进行口服免疫,可诱导针对两种 CF 的特异性血清 IgG+IgM 和粪便 IgA 抗体反应,超过了分别用表达 CFA/I 和 CS2 的天然参考菌株进行免疫接种所诱导的反应。我们得出的结论是,单独或组合表达 ETEC 主要 CF 的描述类型的重组菌可能是有用的候选菌株,可用于口服全细胞 CF-ETEC 疫苗。